Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

Specimen Handling 46Magnetic Resonance Spectroscopy 37Cyclophosphamide 28Vincristine 20Radiation 19Dexamethasone 19Cisplatin 18Biopsy 18Radiotherapy 17Etoposide 17Carboplatin 16Cytarabine 13Leucovorin 12daratumumab 11Methotrexate 11durvalumab 10Standard of Care 10Radiotherapy, Intensity-Modulated 10Platinum 10Gemcitabine 10Doxorubicin 10Docetaxel 10Practice Guidelines as Topic 9Calcium Dobesilate 91,2-diaminocyclohexaneplatinum II citrate 9merphos 8dexamethasone acetate 8dexamethasone 21-phosphate 8auricularum 8X-Rays 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × lanreotide × 90 days × Clear all
NCT06807437 2026-03-31

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

SWOG Cancer Research Network

Phase 3 Recruiting
274 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡